10-Q · May 13, 2026
Vor Biopharma's Q4 2026 10-Q filing reveals continued heavy loss trends with no revenue generated, contrasting sharply with a positive EPS of $307.61 in the prior quarter. Management emphasizes a strategic pivot towards…
Earnings analysis · 10-Q
VOR earnings analysis
Filed August 11, 2026 · Our reading of the company's report
The latest report
Vor Biopharma remains a pre-revenue clinical-stage company with substantial losses, including a $62.8 million second-quarter net loss and a $1,435.4 million accumulated deficit, although losses were sharply lower than…
Read full summary
Vor Biopharma remains a pre-revenue clinical-stage company with substantial losses, including a $62.8 million second-quarter net loss and a $1,435.4 million accumulated deficit, although losses were sharply lower than in the prior-year period. Liquidity improved through $48.4 million of July ATM proceeds, and management expects available funds to support operations into early 2029, but notes that the plan could change and additional financing may be required sooner. The investment case remains dominated by clinical, regulatory, financing and dilution risks surrounding telitacicept.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
What stood out
-
Net Loss Narrowed Sharply
Second-quarter net loss improved materially to $62.8 million from $1,573.7 million in the year-ago quarter. The six-month net loss was $282.4 million versus $1,606.2 million in the prior-year period.
-
Strong Near-Term Liquidity
Liquidity remains substantial: cash, cash equivalents and marketable securities totaled $466.1 million at June 30, 2026, and the company received $48.4 million of net ATM proceeds in July 2026.
-
Cash Runway Extends Into 2029
Management expects the June 30 liquidity, together with the July financing proceeds, to fund operating expenses and capital expenditures into early 2029, subject to changes in the operating plan.
-
Controls Remained Effective
Disclosure controls and procedures were concluded effective at the reasonable-assurance level as of June 30, 2026, and management reported no material changes to internal control over financial reporting during the quarter.
What to watch
-
Persistent Losses and No Revenue
Vor has never generated revenue since inception, reported a six-month net loss of $282.4 million, and had an accumulated deficit of $1,435.4 million as of June 30, 2026. Management expects significant expenses and increasing operating losses for the foreseeable future.
-
Dependence on Future Financing
The company states it has no committed source of additional capital despite needing substantial future funding. Although $466.1 million of liquidity plus $48.4 million of July ATM proceeds is expected to fund operations into early 2029, management warns that funding may be needed sooner if the operating plan changes.
-
Substantial Potential Dilution
Equity overhang and dilution remain material: as of June 30, 2026, 19,522,260 2025 PIPE warrants remained outstanding, along with a 16,000,000-share RemeGen warrant, 7,545,245 options, 604,285 performance stock units and 373,811 restricted stock units.
-
Clinical and Regulatory Execution Risk
Telitacicept is in global Phase 3 trials for gMG and Sjögren’s disease, but the company has not completed clinical development of any product candidate and states it may be years, if ever, before a candidate is ready for commercialization.
-
Higher Reporting and Compliance Costs
The company will lose emerging-growth-company and smaller-reporting-company status after December 31, 2026 because non-affiliate market value exceeded $700 million as of June 30, 2026. It expects increased legal, accounting and financial compliance costs as a large accelerated filer.
Management's outlook
No numeric revenue or EPS guidance was provided. Management states that cash, cash equivalents and marketable securities of $466.1 million as of June 30, 2026, plus $48.4 million of net ATM proceeds received in July 2026, are expected to fund operating expenses and capital expenditures into early 2029; the operating plan may change and funding could be needed sooner.
Earlier filings 4
10-K · March 30, 2026
Vor Biopharma in‑licensed telitacicept in June 2025 and is pivoting to an autoimmune-focused strategy, advancing global Phase 3 programs in gMG and Sjögren’s with positive registrational‑trial data from China supporting…
10-Q · November 13, 2025
Vor Biopharma reported a large net loss in Q3 2025 driven primarily by a non‑cash fair value remeasurement of warrant liabilities: net loss was $(812,684) for the quarter and $(2,418,839) for the nine months. Operating…
10-Q · August 12, 2025
Vor Biopharma reported a deeply negative quarter driven by a $1.30 billion non‑cash revaluation of PIPE warrants, producing a net loss of $1,573,669 (in thousands) and loss per share of $12.56 for the three months ended…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.